Literature DB >> 612209

Endoscopic retrograde cholangiopancreatography. Evaluation based on experience with 805 examinations.

E Seifert.   

Abstract

ERCP was evaluated on the basis of 805 examinations. Visualization of the common bile duct and the pancreatic duct was possible in 44%, of the common bile duct in 22% and of the pancreatic duct alone in 24.6% of the cases. The ductal systems were not opacified in 9.4% but the failure rate decreased from 18.2% to 5.4% within increasing experience. Pathological changes were found in both ducts in 2%, in the common bile duct in 42.2% and the pancreatic duct in 11.4% of the cases. Diagnostic information was supplied by ERCP in 84.4% of the cases. Complications developed in four cases (acute pancreatitis in three and cholangitis in one). There was no mortality in the entire series. It is concluded that ERCP is a valuable diagnostic method that is frequently successful and reasonably safe.

Entities:  

Mesh:

Year:  1977        PMID: 612209

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  4 in total

1.  CT detection of asymptomatic pancreatitis following ERCP.

Authors:  R F Thoeni; S C Fell; H I Goldberg
Journal:  Gastrointest Radiol       Date:  1990

Review 2.  Complications of gastrointestinal radiologic procedures: II. Complications related to biliary tract studies.

Authors:  D J Ott; D W Gelfand
Journal:  Gastrointest Radiol       Date:  1981-01-15

3.  Technetium-99m hexamethylpropylene amine oxime leucocyte scintigraphy in the early course of mild acute pancreatitis following endoscopic retrograde cholangiopancreatography.

Authors:  J C Mortensen; J J Jensen; N Thorsgaard
Journal:  Eur J Nucl Med       Date:  1996-11

4.  Increase in serum bilirubin levels in obstructive jaundice secondary to pancreatic and periampullary malignancy--implications for timing of resectional surgery and use of biliary drainage.

Authors:  S D Mansfield; G Sen; K Oppong; B C Jacques; C B O'Suilleabhain; D M Manas; R M Charnley
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.